Mutation-Driven Immune Microenvironments in Non-Small Cell Lung Cancer: Unrevealing Patterns through Cluster Analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We aimed to comprehensively analyze the immune cell and stromal components of tumor microenvironment at the single cell level and identify tumor heterogeneity among the major top-derived oncogene mutations in non-small cell lung cancer (NSCLC) using single-cell RNA sequencing (scRNA-seq) data. Materials and Methods: The scRNA-seq dataset utilized in this study comprised 64369 primary tumor tissue cells from 21 NSCLC patients, focusing on mutations in EGFR, ALK, BRAF, KRAS, TP53, and the wild-type. Results: Tumor immune microenvironment (TIM) analysis revealed differential immune responses across NSCLC mutation subtypes. TIM analysis revealed different immune responses across the mutation subtypes. Two mutation clusters emerged: KRAS, TP53, and EGFR+TP53 mutations (MC1); and EGFR, BRAF, and ALK mutations (MC2). MC1 showed higher tertiary lymphoid structures signature scores and enriched populations of C2-T-IL7R, C3-T/NK-CXCL4, C9-T/NK-NKG, and C1-B-MS4A1 clusters than cluster 2. Conversely, MC2 cells exhibited higher expression levels of TNF, IL1B, and chemokines linked to alternative immune pathways. Remarkably, co-occurring EGFR and TP53 mutations were grouped as MC1. EGFR+TP53 mutations showed upregulation of peptide synthesis and higher synthetic processes, as well as differences in myeloid and T/NK cells compared to EGFR mutations. In T/NK cells, EGFR+TP53 mutations showed a higher expression of features related to cell activity and differentiation, whereas EGFR mutations showed the opposite. Conclusion: Our research indicates a close association between mutation types and tumor microenvironment in NSCLC, offering insights into personalized approaches for cancer diagnosis and treatment.
Abstract
Purpose: We aimed to comprehensively analyze the immune cell and stromal components of tumor microenvironment at the single cell level and identify tumor heterogeneity among the major top-derived oncogene mutations in non-small cell lung cancer (NSCLC) using single-cell RNA sequencing (scRNA-seq) data. Materials and Methods: The scRNA-seq dataset utilized in this study comprised 64369 primary tumor tissue cells from 21 NSCLC patients, focusing on mutations in EGFR, ALK, BRAF, KRAS, TP53, and the wild-type. Results: Tumor immune microenvironment (TIM) analysis revealed differential immune responses across NSCLC mutation subtypes. TIM analysis revealed different immune responses across the mutation subtypes. Two mutation clusters emerged: KRAS, TP53, and EGFR+TP53 mutations (MC1); and EGFR, BRAF, and ALK mutations (MC2). MC1 showed higher tertiary lymphoid structures signature scores and enriched populations of C2-T-IL7R, C3-T/NK-CXCL4, C9-T/NK-NKG, and C1-B-MS4A1 clusters than cluster 2. Conversely, MC2 cells exhibited higher expression levels of TNF, IL1B, and chemokines linked to alternative immune pathways. Remarkably, co-occurring EGFR and TP53 mutations were grouped as MC1. EGFR+TP53 mutations showed upregulation of peptide synthesis and higher synthetic processes, as well as differences in myeloid and T/NK cells compared to EGFR mutations. In T/NK cells, EGFR+TP53 mutations showed a higher expression of features related to cell activity and differentiation, whereas EGFR mutations showed the opposite. Conclusion: Our research indicates a close association between mutation types and tumor microenvironment in NSCLC, offering insights into personalized approaches for cancer diagnosis and treatment.
참고문헌 (27)
- Thandra KC, "Epidemiology of lung cancer", Contemp Oncol(Pozn), 25, pp.45~52 (2021)
- Leiter A, "The global burden of lung cancer : current status and future trends", Nat Rev Clin Oncol, 20, pp.624~639 (2023)
- Maione P, "Treating advanced non-small cell lung cancer in the elderly", Ther Adv Med Oncol, 2, pp.251~260 (2010)
- Zhou S, "Immunotherapy resistance in non-small-cell lung cancer : from mechanism to clinical strategies", Front Immunol, 14, pp.1129465~ (2023)
- Yan X, "Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer : a retrospective study", J Thorac Dis, 16, pp.1787~1803 (2024)
- Blakely CM, "Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers", Nat Genet, 49, pp.1693~1704 (2017)
- Wang L, "Comparison of the somatic genomic landscape between central-and peripheral-type non-small cell lung cancer", Lung Cancer, 187, pp.107439~ (2024)
- Mansouri S, "Cancer genome and tumor microenvironment : reciprocal crosstalk shapes lung cancer plasticity", Elife, 11, pp.e79895~ (2022)
- Farago AF, "Beyond ALK and ROS1 : RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer", Transl Lung Cancer Res, 6, pp.550~559 (2017)
- Lamberti G, "Beyond EGFR, ALK and ROS1 : current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma", Crit Rev Oncol Hematol, 156, pp.103119~ (2020)
- Santarpia M, "Targeted therapies for KRAS-mutant non-small cell lung cancer : from preclinical studies to clinical developmenta narrative review", Transl Lung Cancer Res, 12, pp.346~368 (2023)
- Skoulidis F, "STK11", LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma, 2018, pp.8, 822~835
- Calles A, "Checkpoint blockade in lung cancer with driver mutation : choose the road wisely", Am Soc Clin Oncol Educ Book, 40, pp.372~384 (2020)
- Wu F, "Single-cell profiling of tumor heterogeneity and the microenvironment in advanced nonsmall cell lung cancer", Nat Commun, 12, pp.2540~ (2021)
- He D, "Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations", Oncogene, 40, pp.355~368 (2021)
- Moghal N, "Single-cell analysis reveals transcriptomic features of drugtolerant persisters and stromal adaptation in a patient-derived EGFR-mutated lung adenocarcinoma xenograft model", J Thorac Oncol, 18, pp.499~515 (2023)
- Hwang B, "Single-cell RNA sequencing technologies and bioinformatics pipelines", Exp Mol Med, 50, pp.1~14 (2018)
- Salcher S, "High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer", Cancer Cell, 40, pp.1503~1520 (2022)
- Laughney AM, "Regenerative lineages and immune-mediated pruning in lung cancer metastasis", Nat Med, 26, pp.259~269 (2020)
- Maynard A, "Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing", Cell, 182, pp.1232~1251 (2020)
- Tan Z, "The role of tumor inflammatory microenvironment in lung cancer", Front Pharmacol, 12, pp.688625~ (2021)
- Tang R, "Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer", Front Immunol, 14, pp.1332814~ (2023)
- Yeo AT, "Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression", Nat Immunol, 23, pp.971~984 (2022)
- Li PH, "Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy", Mil Med Res, 9, pp.52~ (2022)
- Araghi M, "Recent advances in non-small cell lung cancer targeted therapy; an update review", Cancer Cell Int, 23, pp.162~ (2023)